サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：軸性脊椎関節炎治療市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年治療法別、適応症別、エンドユーザー別、企業別、地域別分析
市場調査レポート
商品コード
1289641

軸性脊椎関節炎治療市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年治療法別、適応症別、エンドユーザー別、企業別、地域別分析

Axial Spondyloarthritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Therapy, By Indication, By End User, By Company, and By Region

出版日
ページ情報
英文 112 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

軸性脊椎関節炎治療市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年治療法別、適応症別、エンドユーザー別、企業別、地域別分析
出版日: 2023年06月01日
発行: TechSci Research
ページ情報: 英文 112 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の軸性脊椎関節炎治療市場は、予測期間である2023年から2027年にかけて目覚ましい成長を遂げると予測されています。

軸性脊椎関節炎の発症率の上昇や、この病気に対する社会的認知度の向上などの主な要因が、市場の成長を後押ししています。軸性脊椎関節炎は、軸性骨格に影響を及ぼす慢性炎症性疾患です。軸性脊椎関節炎は、軸性骨格に影響を及ぼす慢性的な炎症性疾患であり、激しい不快感や背中のこわばり、疲労感などが生じます。その他の市場開拓の要因としては、世界人口の増加、研究活動の活発化、患者数の急増、多数の臨床試験、製品の革新と開発の増加、研究開発への多額の投資、一人当たりの医療費の増加、軸性脊椎関節炎の有病率の増加、M&Aの増加、既存の医療インフラの改善に対するいくつかの当局の強調があげられます。

軸性脊椎関節炎の発生件数の急増

軸性脊椎関節炎の有病率が世界的に上昇していることが、市場の成長を後押ししています。軸性脊椎関節炎の原因は不明ですが、いくつかの調査の結果、遺伝子が特定の細菌、ウイルス、またはその他の誘因にさらされることによって引き起こされると推測されています。患者さんは、患部のこわばりや疲労感など、深刻な不調に見舞われます。また、高齢者だけでなく、若い世代にも発症しやすい病気です。このような要因が、世界の市場の成長を後押ししています。米国では、約270万人以上の米国人が軸性脊椎関節炎（axSpA）に罹患しているとの調査結果もあります。

承認されたバイオシミラー医薬品の増加

世界保健機関（WHO）によると、バイオシミラーとは、すでに認可されているオリジナルのバイオ治療薬と安全性、品質、有効性の点で類似しているバイオ治療薬のことを指します。バイオシミラーとは、軸性脊椎関節炎などの治療に役立つ生物学的製剤です。患者さんにとって非常に有効であり、その入手のしやすさから先発品に取って代わられました。過去数年間、軸性脊椎関節炎の治療薬として承認されたバイオシミラーの数は急増しており、これが世界の市場の成長を後押ししています。例えば、2020年と2021年に米国食品医薬品局は、軸性脊椎関節炎の患者を治療するための3つの新規製品、すなわちXeljanz、Taltz、およびCosentyxを承認しました。

研究開発活動の活発化

分子生物学および免疫学分野における研究開発活動の活発化は、市場の成長を後押ししています。研究活動の増加により、腫瘍壊死因子（TNF）阻害剤、IL-23、インターロイキン（IL）-17阻害剤などの新規生物学的製剤の出現が急増しています。例えば、2022年、世界のバイオ医薬品企業であるUCBは、第3相BE MOBILE 1試験が主要評価項目およびランク付けされたすべての副次評価項目を達成したというトップライン中間解析結果を発表しました。BE MOBILE 1は、活動性の非放射線性軸索関節炎（nr-axSpA）を患う成人を対象に、ビメキズマブの有効性と安全性を測定する主要試験です。さらに、政府による研究活動への投資の高まりが、市場の成長を促進しています。

利用可能なカスタマイズ

TechSci Researchは、与えられた市場データをもとに、企業の特定のニーズに応じたカスタマイズを提供します。本レポートでは、以下のカスタマイズが可能です：

企業情報

  • 追加市場プレイヤーの詳細分析とプロファイリング（最大5社）。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 軸性脊椎関節炎治療の世界市場に対するCOVID-19の影響

第5章 顧客の声（VOC ）

第6章 臨床試験分析

第7章 軸性脊椎関節炎治療の世界市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • 治療法別（抗腫瘍壊死因子（TNF）療法、抗インターロイキン（IL）療法、抗ヤヌスキナーゼ（JAK）療法）
    • 適応症別（強直性脊椎炎／非放射線性軸性脊椎関節炎治療）
    • エンドユーザー別（病院・診療所、学術・調査機関、その他）
    • 地域別
    • 企業別（2021年）
  • 市場マップ

第8章 北米の軸性脊椎関節炎治療の市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェア・予測
    • 治療法別
    • 適応症別
    • エンドユーザー別
    • 国別
  • 北米の国別分析
    • 米国
    • カナダ
    • メキシコ

第9章 欧州の軸性脊椎関節炎治療の市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • 治療法別
    • 適応症別
    • エンドユーザー別
    • 国別
  • 欧州の国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第10章 アジア太平洋地域の軸性脊椎関節炎治療の市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • 治療法別
    • 適応症別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域の国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第11章 南米の軸性脊椎関節炎治療の市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • 治療法別
    • 適応症別
    • エンドユーザー別
    • 国別
  • 南米の国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第12章 中東・アフリカの軸性脊椎関節炎治療の市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • 治療法別
    • 適応症別
    • エンドユーザー別
    • 国別
  • MEAの国別分析
    • 南アフリカ
    • サウジアラビア
    • UAE

第13章 市場力学

  • 促進要因
  • 課題

第14章 市場の動向と開拓

第15章 競合情勢（包括的なSWOT分析）

  • Novartis International, AG
  • Eli Lilly and Company
  • Johnson & Johnson
  • UCB S.A.
  • Pfizer, Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • FunPep Co., Ltd.

第16章 戦略的提言

目次
Product Code: 13053

The global axial spondyloarthritis treatment market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors, including the rising incidence of axial spondyloarthritis and increasing public awareness of the disease, are propelling the growth of the market. Axial spondyloarthritis is a chronic inflammatory condition that impacts the axial skeleton. The person undergoes severe discomfort, stiffness in the back area, and fatigue because of it. The other factors supporting the market's growth are the growing world population, increasing research activities, a surge in the number of patients, a large number of clinical trials, rising product innovation and development, significant investment in research and development, rising per capita health care expenditure, increasing prevalence of axial spondyloarthritis, growing number of mergers and acquisitions, and rising emphasis of several authorities on improving existing healthcare infrastructure.

A surge in Incidences of Axial Spondylarthritis

The increasing prevalence of axial spondylarthritis across the globe is bolstering the growth of the market. The cause of axial spondylarthritis is not known, but after several research, it is assumed that it is caused due to the exposure of genes to certain bacteria, viruses, or other triggers. Patients undergo serious discomforts, such as stiffness in the affected part and fatigue. Not only the elderly population but the younger generation are also prone to the disease. Therefore, these factors are bolstering the growth of the market globally. According to a cited study, in the U.S., about 2.7 million Americans or more are affected by axial spondyloarthritis (axSpA).

Increase in the Number of Approved Biosimilars

According to the World Health Organization (WHO), Biosimilars refer to a biotherapeutic product that is similar in terms of safety, quality, and efficacy to an already licensed original biotherapeutic product. Biosimilars are biological drugs that help in treating diseases such as axial spondylarthritis. They are very effective in patients and have replaced originator drugs due to their greater accessibility. In the past few years, there has been a surge in the number of approved biosimilars for the treatment of axial spondylarthritis, which is augmenting the growth of the market globally. For instance, in 2020 and 2021, the U.S. Food and Drug Administration approved three novel products, i.e., Xeljanz, Taltz, and Cosentyx, to treat individuals with axial spondyloarthritis.

Increasing R&D Activities

Rise in research and development (R&D) activities in the molecular and immunologic field are propelling the growth of the market. Owing to the increase in research activities, the advent of novel biologic agents such as tumor necrosis factor (TNF) inhibitors, IL-23, and interleukin (IL)-17 inhibitors are surging. For instance, in 2022, UCB, a global biopharmaceutical company, announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met the primary and all ranked secondary endpoints. BE MOBILE 1 is the primary study to measure the effectiveness and safety of bimekizumab in adults suffering from active non-radiographic axial spondyloarthritis (nr-axSpA). Moreover, the rising investments in the research activities by the government are facilitating the growth of the market.

Market Segmentation

The global axial spondyloarthritis treatment market is segmented into therapy, indication, end user, and company. Based on therapy, the market is divided into anti-tumor necrosis factor (TNF) therapy, anti-interleukin (IL) therapy, and anti-Janus kinase (JAK) therapy. Based on indication, the market is divided into ankylosing spondylitis and non-radiographic axial spondyloarthritis treatment. Based on end-user, the market is divided into hospitals & clinics, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rise in R&D activities in the country.

Market Players

Novartis International, AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Pfizer, Inc., Kyowa Kirin Co., Ltd., Merck & Co., Inc., AbbVie Inc, Bristol-Myers Squibb Company, and FunPep Co., Ltd. are some of the leading companies operating in the market.

Report Scope

In this report, global axial spondyloarthritis treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Axial Spondyloarthritis Treatment Market, By Therapy:

  • Anti-Tumor Necrosis Factor (TNF) Therapy
  • Anti-Interleukin (IL) Therapy
  • Anti-Janus Kinase (JAK) Therapy

Axial Spondyloarthritis Treatment Market, By Indication:

  • Ankylosing Spondylitis
  • Non-radiographic Axial Spondyloarthritis Treatment

Axial Spondyloarthritis Treatment Market, By End User:

  • Hospitals & Clinics
  • Academic & Research Institutions
  • Others

Axial Spondyloarthritis Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Axial Spondyloarthritis Treatment Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Axial Spondyloarthritis Treatment Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Global Axial Spondyloarthritis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy (Anti-Tumor Necrosis Factor (TNF) Therapy, Anti-Interleukin (IL) Therapy, Anti-Janus Kinase (JAK) Therapy)
    • 7.2.2. By Indication (Ankylosing Spondylitis v/s Non-radiographic Axial Spondyloarthritis Treatment)
    • 7.2.3. By End User (Hospitals & Clinics, Academic & Research Institutions, Others)
    • 7.2.4. By Region
    • 7.2.5. By Company (2021)
  • 7.3. Market Map

8. North America Axial Spondyloarthritis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Indication
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Axial Spondyloarthritis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End User
    • 8.3.2. Canada Axial Spondyloarthritis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End User
    • 8.3.3. Mexico Axial Spondyloarthritis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End User

9. Europe Axial Spondyloarthritis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Indication
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Axial Spondyloarthritis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End User
    • 9.3.2. Germany Axial Spondyloarthritis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End User
    • 9.3.3. United Kingdom Axial Spondyloarthritis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End User
    • 9.3.4. Italy Axial Spondyloarthritis Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapy
        • 9.3.4.2.2. By Indication
        • 9.3.4.2.3. By End User
    • 9.3.5. Spain Axial Spondyloarthritis Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapy
        • 9.3.5.2.2. By Indication
        • 9.3.5.2.3. By End User

10. Asia-Pacific Axial Spondyloarthritis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Indication
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Axial Spondyloarthritis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End User
    • 10.3.2. India Axial Spondyloarthritis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End User
    • 10.3.3. Japan Axial Spondyloarthritis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End User
    • 10.3.4. South Korea Axial Spondyloarthritis Treatment Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Therapy
        • 10.3.4.2.2. By Indication
        • 10.3.4.2.3. By End User
    • 10.3.5. Australia Axial Spondyloarthritis Treatment Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Therapy
        • 10.3.5.2.2. By Indication
        • 10.3.5.2.3. By End User

11. South America Axial Spondyloarthritis Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapy
    • 11.2.2. By Indication
    • 11.2.3. By End User
    • 11.2.4. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Axial Spondyloarthritis Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapy
        • 11.3.1.2.2. By Indication
        • 11.3.1.2.3. By End User
    • 11.3.2. Argentina Axial Spondyloarthritis Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapy
        • 11.3.2.2.2. By Indication
        • 11.3.2.2.3. By End User
    • 11.3.3. Colombia Axial Spondyloarthritis Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapy
        • 11.3.3.2.2. By Indication
        • 11.3.3.2.3. By End User

12. Middle East and Africa Axial Spondyloarthritis Treatment Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Therapy
    • 12.2.2. By Indication
    • 12.2.3. By End User
    • 12.2.4. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Axial Spondyloarthritis Treatment Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Therapy
        • 12.3.1.2.2. By Indication
        • 12.3.1.2.3. By End User
    • 12.3.2. Saudi Arabia Axial Spondyloarthritis Treatment Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Therapy
        • 12.3.2.2.2. By Indication
        • 12.3.2.2.3. By End User
    • 12.3.3. UAE Axial Spondyloarthritis Treatment Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Therapy
        • 12.3.3.2.2. By Indication
        • 12.3.3.2.3. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape (Inclusive SWOT Analysis)

  • 15.1. Novartis International, AG
  • 15.2. Eli Lilly and Company
  • 15.3. Johnson & Johnson
  • 15.4. UCB S.A.
  • 15.5. Pfizer, Inc.
  • 15.6. Kyowa Kirin Co., Ltd.
  • 15.7. Merck & Co., Inc.
  • 15.8. AbbVie Inc
  • 15.9. Bristol-Myers Squibb Company
  • 15.10. FunPep Co., Ltd.

16. Strategic Recommendations